A detailed history of Thrivent Financial For Lutherans transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 29,206 shares of ARWR stock, worth $553,745. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,206
Previous 30,009 2.68%
Holding current value
$553,745
Previous $780,000 27.44%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$19.36 - $29.54 $15,546 - $23,720
-803 Reduced 2.68%
29,206 $566,000
Q2 2024

Aug 13, 2024

SELL
$21.87 - $28.24 $22,722 - $29,341
-1,039 Reduced 3.35%
30,009 $780,000
Q1 2024

May 14, 2024

BUY
$27.21 - $39.48 $116,186 - $168,579
4,270 Added 15.95%
31,048 $888,000
Q4 2023

Feb 14, 2024

SELL
$21.2 - $31.03 $1,314 - $1,923
-62 Reduced 0.23%
26,778 $819,000
Q3 2023

Nov 14, 2023

SELL
$26.2 - $36.08 $1.8 Million - $2.48 Million
-68,820 Reduced 71.94%
26,840 $721,000
Q2 2023

Aug 14, 2023

BUY
$25.16 - $41.38 $1.69 Million - $2.78 Million
67,076 Added 234.66%
95,660 $3.41 Million
Q1 2023

May 17, 2023

BUY
$23.68 - $38.51 $9,235 - $15,018
390 Added 1.38%
28,584 $726,000
Q4 2022

Feb 08, 2023

BUY
$28.0 - $40.56 $5,012 - $7,260
179 Added 0.64%
28,194 $1.14 Million
Q3 2022

Nov 14, 2022

BUY
$29.63 - $48.31 $8,148 - $13,285
275 Added 0.99%
28,015 $926,000
Q2 2022

Aug 16, 2022

BUY
$27.79 - $50.61 $5,057 - $9,211
182 Added 0.66%
27,740 $977,000
Q1 2022

May 13, 2022

SELL
$39.62 - $69.97 $580,829 - $1.03 Million
-14,660 Reduced 34.72%
27,558 $1.27 Million
Q4 2021

Feb 16, 2022

BUY
$58.09 - $82.51 $13,825 - $19,637
238 Added 0.57%
42,218 $3.04 Million
Q3 2021

Nov 15, 2021

SELL
$58.38 - $84.96 $22,126 - $32,199
-379 Reduced 0.89%
41,980 $2.62 Million
Q2 2021

Sep 24, 2021

BUY
$62.15 - $90.32 $915,345 - $1.33 Million
14,728 Added 53.3%
42,359 $3.51 Million
Q2 2021

Aug 19, 2021

SELL
$62.15 - $90.32 $5.08 Million - $7.39 Million
-81,803 Reduced 74.75%
27,631 $2.29 Million
Q1 2021

May 17, 2021

SELL
$61.35 - $90.47 $472,456 - $696,709
-7,701 Reduced 6.57%
109,434 $7.26 Million
Q4 2020

Feb 16, 2021

BUY
$43.82 - $85.37 $3.28 Million - $6.39 Million
74,867 Added 177.12%
117,135 $8.99 Million
Q3 2020

Nov 10, 2020

BUY
$33.21 - $51.27 $470,054 - $725,675
14,154 Added 50.35%
42,268 $1.82 Million
Q2 2020

Aug 12, 2020

BUY
$26.12 - $43.27 $51,116 - $84,679
1,957 Added 7.48%
28,114 $1.21 Million
Q4 2019

Feb 13, 2020

SELL
$28.14 - $73.01 $1.39 Million - $3.61 Million
-49,502 Reduced 65.43%
26,157 $1.66 Million
Q3 2019

Nov 14, 2019

BUY
$26.26 - $34.86 $46,112 - $61,214
1,756 Added 2.38%
75,659 $2.13 Million
Q2 2019

Aug 13, 2019

BUY
$17.43 - $28.82 $1.29 Million - $2.13 Million
73,903 New
73,903 $1.96 Million

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.01B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Thrivent Financial For Lutherans Portfolio

Follow Thrivent Financial For Lutherans and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.